Skip to main content
. Author manuscript; available in PMC: 2018 Jun 21.
Published in final edited form as: Oncogene. 2018 Mar 7;37(24):3216–3228. doi: 10.1038/s41388-018-0126-2

Figure 2. MTL-CEBPA increases liver expression of CEBPA in DEN induced HCC Wistar rats.

Figure 2

(A) MTL-CEBPA showed a significant increase in CEBPAmRNA: **, p<0.001. Albumin showed a tedency to increase after MTL-CEBPA treatment, however this was not statistically significant (p=0.1769). Tumour nodule size and liver function tests were assessed in the DEN induced cirrhotic HCC animals. (B) Liver tumour nodule size was measured from the biopsies across the pre-treatment control and two treatment groups. The average tumour size in the DEN only group (pre-treatment) was 193 (± 63) mm3. Over the 12-day course of the study period, the tumour size of animals treated with NOV340/FLUC at time of termination increased to 2204 (± 1031) mm3. All animals treated with MTL-CEBPA showed a slower rate of increase with an average volume of 401 (± 181)mm3 (p=0.107 vs. NOV340/FLUC control). (C) Liver function parameters were measured for AST, ALT, albumin and bilirubin. All showed a 30-50% decrease over the short study period. Ammonia decreased significantly despite the small group size. *, p<0.02).